DRW Securities’s Prevail Therapeutics PRVL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
– Sell
-49,426
Closed -$652K – 182
2019
Q2
$652K Buy
+49,426
New +$720K 0.04% 63

Other funds holding PRVL

DRW Securities's PRVL Position: Q3 2019 in Review

DRW Securities sold out of Prevail Therapeutics (PRVL) in Q3 2019, closing a stake of 49,426 shares — an estimated $652K sold.

DRW Securities first reported a position in PRVL in Q2 2019 and held it in 1 quarter. The position peaked at $652K in Q2 2019. 42 funds tracked by Wall St. Rank hold PRVL as of Q3 2019.

  • DRW Securities reported no remaining Prevail Therapeutics position as of Q3 2019 after selling out during the quarter.
  • DRW Securities sold 49,426 Prevail Therapeutics shares in Q3 2019, an estimated $652K.
  • DRW Securities first reported a position in Prevail Therapeutics in Q2 2019 and held it in 1 quarter.
  • DRW Securities's Prevail Therapeutics position peaked at $652K in Q2 2019.
  • 42 funds tracked by Wall St. Rank held Prevail Therapeutics as of Q3 2019.

Based on DRW Securities's 13F filing for Q3 2019, filed 14 Nov 2019.